(WEAV) Weave Communications - Ratings and Ratios
Phone, Text, Payments, Reviews, Analytics
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.8% |
| Value at Risk 5%th | 81.6% |
| Relative Tail Risk | -11.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.30 |
| Alpha | -74.13 |
| CAGR/Max DD | 0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.430 |
| Beta | 1.640 |
| Beta Downside | 1.820 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.66% |
| Mean DD | 23.55% |
| Median DD | 18.35% |
Description: WEAV Weave Communications October 23, 2025
Weave Communications Inc. (NYSE: WEAV) delivers an integrated, cloud-based platform that combines patient-engagement, practice-management, and payments tools for small- and medium-sized healthcare providers, including dental service organizations, vision, veterinary and medical groups.
Core capabilities include a unified phone system that distinguishes new versus returning patients, softphone and mobile apps for remote calling, automated text-reply workflows, team chat, AI-driven call intelligence, email marketing, online scheduling, digital forms, insurance verification, and a payments processor that captures point-of-service transactions. The suite also offers review-management tools, practice analytics (real-time retention, scheduling, treatment acceptance and revenue metrics), and an enterprise tier for multi-location practices.
Founded in 2008 as Recall Solutions and rebranded to Weave in 2015, the company is headquartered in Lehi, Utah, and operates within the GICS Application Software sub-industry.
**Recent performance highlights (FY 2023):**
• Revenue ≈ $215 million, up ~30% YoY, driven by strong adoption of the payments and AI modules.
• Annual recurring revenue (ARR) surpassed $200 million with a net dollar retention rate of roughly 115%, indicating effective upselling to existing practices.
• Gross margin held near 70% and churn remained below 5% on a quarterly basis, reflecting the sticky nature of the SaaS-plus-payments model.
**Sector drivers:** The U.S. healthcare SaaS market is expanding at a 12% compound annual growth rate, fueled by rising administrative cost pressures and the accelerating shift toward digital front-office solutions. Additionally, consumer demand for seamless, omnichannel communication (phone, text, chat) and the broader adoption of electronic payments in outpatient settings are creating tailwinds for platforms that bundle these functions.
For a deeper dive into WEAV’s valuation metrics and peer comparisons, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (-32.9m TTM) > 0 and > 6% of Revenue (6% = 13.8m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 3.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.72% (prev 23.27%; Δ -14.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 18.0m > Net Income -32.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.24 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (75.7m) change vs 12m ago 5.11% (target <= -2.0% for YES) |
| Gross Margin 71.93% (prev 70.68%; Δ 1.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 115.3% (prev 102.0%; Δ 13.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -18.88 (EBITDA TTM -13.3m / Interest Expense TTM 1.70m) >= 6 (WARN >= 3) |
Altman Z'' -8.06
| (A) 0.10 = (Total Current Assets 103.0m - Total Current Liabilities 82.9m) / Total Assets 206.5m |
| (B) -1.54 = Retained Earnings (Balance) -317.2m / Total Assets 206.5m |
| warn (B) unusual magnitude: -1.54 — check mapping/units |
| (C) -0.16 = EBIT TTM -32.1m / Avg Total Assets 199.2m |
| (D) -2.48 = Book Value of Equity -317.5m / Total Liabilities 127.8m |
| Total Rating: -8.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.91
| 1. Piotroski 5.50pt |
| 2. FCF Yield 3.27% |
| 3. FCF Margin 7.03% |
| 4. Debt/Equity 0.67 |
| 5. Debt/Ebitda 0.86 |
| 6. ROIC - WACC (= -55.25)% |
| 7. RoE -44.93% |
| 8. Rev. Trend 99.85% |
| 9. EPS Trend 65.91% |
What is the price of WEAV shares?
Over the past week, the price has changed by +8.85%, over one month by +10.57%, over three months by -8.60% and over the past year by -54.95%.
Is WEAV a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the WEAV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.4 | 48.6% |
| Analysts Target Price | 10.4 | 48.6% |
| ValueRay Target Price | 6.1 | -13.1% |
WEAV Fundamental Data Overview December 11, 2025
P/S = 2.2682
P/B = 6.6298
Beta = 1.719
Revenue TTM = 229.8m USD
EBIT TTM = -32.1m USD
EBITDA TTM = -13.3m USD
Long Term Debt = 53.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 53.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.3m USD (from netDebt column, last quarter)
Enterprise Value = 494.0m USD (521.2m + Debt 53.0m - CCE 80.3m)
Interest Coverage Ratio = -18.88 (Ebit TTM -32.1m / Interest Expense TTM 1.70m)
FCF Yield = 3.27% (FCF TTM 16.2m / Enterprise Value 494.0m)
FCF Margin = 7.03% (FCF TTM 16.2m / Revenue TTM 229.8m)
Net Margin = -14.32% (Net Income TTM -32.9m / Revenue TTM 229.8m)
Gross Margin = 71.93% ((Revenue TTM 229.8m - Cost of Revenue TTM 64.5m) / Revenue TTM)
Gross Margin QoQ = 72.29% (prev 71.75%)
Tobins Q-Ratio = 2.39 (Enterprise Value 494.0m / Total Assets 206.5m)
Interest Expense / Debt = 0.69% (Interest Expense 366.0k / Debt 53.0m)
Taxrate = -0.96% (negative due to tax credits) (82.0k / -8.59m)
NOPAT = -32.4m (EBIT -32.1m * (1 - -0.96%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.24 (Total Current Assets 103.0m / Total Current Liabilities 82.9m)
Debt / Equity = 0.67 (Debt 53.0m / totalStockholderEquity, last quarter 78.6m)
Debt / EBITDA = 0.86 (negative EBITDA) (Net Debt -11.3m / EBITDA -13.3m)
Debt / FCF = -0.70 (Net Debt -11.3m / FCF TTM 16.2m)
Total Stockholder Equity = 73.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.94% (Net Income -32.9m / Total Assets 206.5m)
RoE = -44.93% (Net Income TTM -32.9m / Total Stockholder Equity 73.3m)
RoCE = -25.41% (EBIT -32.1m / Capital Employed (Equity 73.3m + L.T.Debt 53.0m))
RoIC = -44.24% (negative operating profit) (NOPAT -32.4m / Invested Capital 73.3m)
WACC = 11.01% (E(521.2m)/V(574.3m) * Re(12.06%) + D(53.0m)/V(574.3m) * Rd(0.69%) * (1-Tc(-0.01)))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.19%
[DCF Debug] Terminal Value 54.74% ; FCFE base≈12.7m ; Y1≈8.36m ; Y5≈3.82m
Fair Price DCF = 0.58 (DCF Value 44.9m / Shares Outstanding 78.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 65.91 | EPS CAGR: 189.3% | SUE: 0.13 | # QB: 0
Revenue Correlation: 99.85 | Revenue CAGR: 19.11% | SUE: 1.60 | # QB: 12
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=-0.010 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=-0.020 | Revisions Net=+1 | Growth EPS=+41.6% | Growth Revenue=+15.1%
Additional Sources for WEAV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle